Induction of killer cells from lymphocytes in pleural effusion of advanced lung cancer patients

Jpn J Cancer Res. 1990 Oct;81(10):1012-20. doi: 10.1111/j.1349-7006.1990.tb03339.x.


We analyzed the phenotype and cytotoxic ability of pleural exudative lymphocytes (PLEL) which were obtained from 18 advanced lung cancer patients. Freshly isolated PLEL were mainly CD4(+) T cells and had weak natural killer, autologous tumor killing and lymphokine-activated killer activities. After cultivation of PLEL with interleukin-2, cytotoxicity of PLEL against autologous tumor cells was increased at 2 weeks, but it was remarkably reduced at 4 weeks. When PLEL were stimulated by mitomycin C-treated autologous tumor cells during culture, autologous tumor killing activity of PLEL was significantly enhanced even after 4 weeks of cultivation. Cold target inhibition analysis and binding inhibition assays using monoclonal antibodies indicated that autologous tumor stimulation could induce major histocompatibility complex class I restricted cytotoxic T lymphocytes specific for autologous tumor cells in some cases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / immunology
  • Adenocarcinoma / pathology*
  • Adult
  • Aged
  • Carcinoma, Small Cell / immunology
  • Carcinoma, Small Cell / pathology*
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / pathology*
  • Cytotoxicity, Immunologic / immunology
  • Female
  • Humans
  • Interleukin-2 / pharmacology
  • Killer Cells, Natural / immunology*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / pathology*
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / physiology
  • Lymphocytes / drug effects
  • Male
  • Middle Aged
  • Pleural Effusion, Malignant / immunology
  • Pleural Effusion, Malignant / pathology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Tumor Cells, Cultured


  • Interleukin-2